CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill…

Both Phase 2 and Phase 2b/3 trials for COVID-19 patients will be discussed

VANCOUVER, Washington, April 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief executive Officer of CytoDyn will appear on Fox Business Network on the Making Money with Charles Payne program. The program will air from 2:00 pm ET to 3:00 pm ET (11:00 am PT to 12 noon PT) and is also available via live streaming at https://www.foxbusiness.com/shows/making-money-with-charles-payne.

The Companys investigational new drug, leronlimab, has been administered to 10 severely ill patients with COVID-19 at a leading medical center in the New York City area under an emergency IND recently granted by the FDA. The Company recently initiated enrollment in a Phase 2 trial for leronlimab treatment of COVID-19 patients with mild-to-moderate indications and under the same IND, is now proceeding with its second COVID-19 clinical, a Phase 2b/3 trial for the treatment of critically ill patients.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

Story continues

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

Continue reading here:
CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill...

PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting…

PharmAbcine Inc. (KOSDAQ: 208340) announced today that the abstract summarizing interim data on its phase Ib trial of olinvacimab in combination with Mercks anti-PD-1 antibody Keytruda for recurrent glioblastoma multiforme (rGBM) patients has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Phase Ib study is to evaluate the safety of the combination therapy of two agents for rGBM patients and to explore appropriate clinical dose levels of the two agents as in a combination regimen. During the study, 200 mg of Keytruda was administered to patients every three weeks while 12 or 16 mg/kg of olinvaciamb was administered on a weekly basis. From the phase Ib study, there was no DLT (dose limiting toxicity) observed, and among 9 patients, 4 patients had SD (stable disease) and 5 patients experienced disease progression (PD).

rGBM is a rare tumor and there are only a few treatment options available to date. It is known to have the worst prognosis among any other types of cancers/tumors and the life expectancy of rGBM patients is less than 4 months upon diagnosis. There have been multiple clinical trials using immuno-oncology drugs to treat rGBM but the promising results have not been reported yet.

Previously Olinvacimab from its phase IIa clinical study in rGBM patients ascertained its significant improvement of brain edema and shrinkage of tumor. Now its use is being investigated in a phase II study for Avastin-refractory rGBM patients in US and Australia.

An ASCO annual meeting is a global conference, annually accommodating 40,000 people from 76 different countries.

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders and tumors by targeting molecules involved in angiogenesis and immune checkpoints, which are responsible for hindrance in immune response to tumors. Our innovative discovery technology coupled with dedicated R&D staff have enabled us to provide superlative therapeutic antibodies for a wide array of indications in oncology, immuno-oncology, ophthalmology, and renal pathology.

PharmAbcines HuPhage library and innovative selection system are priceless proprietary assets that can generate antibodies with greater diversity than 10^11.

PharmAbcines advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With our highly advanced technology platforms, we provide high-quality antibody generation services.

PharmAbcines advanced evaluation platforms can facilitate the pipeline development by assessing its anti-tumor effects with greater precision and accuracy. Through the collaboration with Samsun Medical Centre, We have more than 300 patients-derived cancer stem cell libraries and a PDX (patient-derived xenograft) animal model system to evaluate internal pipeline development.

Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com

Contacts

Yohan Jung

82-42-863-2017

yohan.jung@pharmabcine.com

Read the original:
PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting...

North Jersey hitting the surge – Politico

This shouldnt come as a surprise given what New Jerseyans are seeing right across the river. But Im still a little taken aback with how little people are talking about it.

Yesterday, Health Commissioner Judith Persichilli said "It looks like the surge is beginning to occur in the northern part of the state.

Advertisement

Gov. Murphy acknowledged New Jersey will soon need refrigerated trucks for the bodies of coronavirus victims.

I dont have a specific day, but soon, Murphy said yesterday. The fact that were having this conversation, folks, means this is real.

Send tips to [emailprotected]

QUOTE OF THE DAY: There's no greater intervention, period, full stop, none, than physical distancing. California Gov. Gavin Newsom on CNN. (I bet you thought it was someone else)

WHERES MURPHY?: In Secaucus at 10 a.m. to tour the field hospital at the Meadowlands Exposition Center, then in Trenton for his daily briefing at 1 p.m.

HAPPY BIRTHDAY: My cousin Amanda, Princetons Brent Colburn, MBIs Michele Jaker, Environment New Jerseys Doug OMalley, Optimus Partners David Vitali

CORONAVIRUS TRACKER: The latest: 3,649 newly-diagnosed cases in New Jersey for a total of 22,255 since the pandemic hit. Ninety-one new deaths, for a total of 355.

Sign up for POLITICO Nightly: Coronavirus Special Edition, your daily update on how the illness is affecting politics, markets, public health and more.

THE ANTI-CHRISTIE In New Jersey, a quieter alternative to Cuomo leads the pandemic response, by POLITICOs Matt Friedman: In a matter of hours last month, New Jersey Gov. Phil Murphy went from dealing with the biggest personal health crisis of his life to overseeing the biggest health crisis his state has faced in more than a century. On March 4, Murphy reported to a New York City hospital at dawn for a surgical procedure in which doctors removed a cancerous tumor from his left kidney. Fourteen hours later, while recovering in his hospital bed, Murphy approved a statement from his office announcing New Jerseys first known case of the coronavirus. Since then, New Jersey has seen more than 22,000 of its residents test positive for Covid-19 and more than 350 die as the state is now the second-biggest hot spot in the nation behind New York. While New York Gov. Andrew Cuomo has become the national medias go-to governor as he deals with that states outbreak with tough talk and sometimes harsh, sometimes cajoling words for President Donald Trump, Murphy known locally more for his taste in Allbirds footwear and dad jokes than for being a disciplinarian has maintained a gentler, folksier style as he manages the crisis from the other side of the Hudson River.

STATEHOUSE REPORTERS LOOK FORWARD TO HARD CIDER DURING NEGOTIATION STAKE OUTS New Jersey to extend tax filing deadline to July 15, budget deadline to Sept. 30, by POLITICOs Katherine Landergan: New Jersey will extend the tax filing deadline to July 15 and the deadline for passing a state budget to Sept. 30, Gov. Phil Murphy and legislative leaders announced Wednesday morning. The state budget is typically due June 30, but that date is being pushed back three months to deal with severe financial disruptions caused by the coronavirus pandemic. The ongoing COVID-19 pandemic has caused hardships, financial strain, and disruptions for many New Jerseyans and New Jersey businesses. As part of our response, we have reached agreement that the state income tax filing deadline and the corporation business tax filing deadline will be extended from April 15 to July 15, Murphy, Senate President Steve Sweeney and Assembly Speaker Craig Coughlin said in a statement. Additionally, as part of the whole-of-government effort that is going into fighting COVID-19, we have agreed that the state fiscal year should be extended to September 30th, the statement said. This will allow the Administration and the Legislature to focus fully on leading New Jersey out of this crisis, and to allow for a robust, comprehensive, and well-informed budget process later in the year.

WHO COULDVE PREDICTED A DANGEROUS VIRUS COULD CAUSE PROBLEMS? Coronavirus in NJ: State was warned in 2015 about 'catastrophic' impact a flu-like disease could have, by The Asbury Park Press Michael L. Diamond: The New Jersey Department of Health updated its emergency influenza plan in 2015, predicting a devastating impact on the state if it were to get hit by a disease similar to the Spanish flu a century ago. It said nearly a third of the population would contract the illness, 277,000 would need to be hospitalized and 5,000 would die. Put into motion by the coronavirus, though, the blueprint has exposed shortfalls in preparation that have forced government and health leaders to improvise, leaving health care workers and patients at risk. In hindsight, we all should have paid attention" to the plan, said state Sen. Declan O'Scanlon, R-Monmouth. 'But without any frame of reference, it would have been hard to do.

BUILD THE WALL To stop coronavirus, Murphy wants to keep the 'lowest common denominator' out of NJ, by The Records Charles Stile: Coronavirus has converted Phil Murphy into a close-the-border hardliner. The liberal New Jersey governor, who daily invokes a 'One New Jersey family' slogan of solidarity, inclusiveness, now wants to keep 'the lowest common denominator' from traveling into the Garden State. By that he means people traveling in from other states that have been slow to take the threat seriously by refusing to close their beaches during spring break or shut down mega-churches where faith supersedes science. Murphy said he fears out-of-staters will restart the fire; or spark a second wave of infections and deaths when New Jersey life begins returning to normal his remarks are also puzzling that they come only two days after President Trump floated his own an unenforceable and constitutionally questionable travel ban of New Jersey, New York and Connecticut residents."

LUXURY APARTMENTS ARE ESSENTIAL Some NJ construction workers fear virus exposure as they continue to work, by News 12s Walt Kane: While most of New Jersey is under a stay at home order, construction workers across New Jersey are on the job. And some tell Kane In Your Corner the situation has them concerned for their safety, There's no social distancing at all, a construction worker says. I don't know why this is still going on. He's one of the hundreds who report to a job site in Jersey City each morning. Like all construction projects in the state, it's been deemed essential by Gov. Phil Murphy. But the project in question is Jersey Squared, a large, luxury high-rise complex in Journal Square that's been under construction, in stages, for years. The worker says he doesn't think it's essential at all. Other states, including New York, have taken a different approach to construction, shutting down all but essential projects.

SORRY ABOUT THAT BUT THANKS FOR THE REVENUE Pandemic isolation, shift to online gambling set up 'perfect storm,' experts say, by The Press of Atlantic Citys David Danzis: Gov. Phil Murphy ordered the indefinite closing of Atlantic Citys nine casinos March 16 but permitted online gaming to continue. Industry experts expect an escalation in online gaming activity because of the retail casino closings, and the anticipated growth in internet play has gambling addiction professionals worried. We believe every risk factor for gambling problems is increasing right now, said Keith Whyte, executive director of the National Council on Problem Gambling. The social distancing measures recommended by government health officials exacerbate conditions such as loneliness, isolation and depression that lead to problem behaviors, Whyte said.

HCQ OR CIALIS? In my bone of bones, I think this works: Pennacchio on HCQ, by InsiderNJs Fred Snowflack: Joe Pennacchio is no stranger to plunging ahead to make a point. He did that 26 years ago with a long shot primary challenge to Dean Gallo, a popular congressman. Now a state senator from Montville (LD-26) and also a co-chair of Donald Trumps New Jersey reelection effort, Pennacchio is energetically championing another and much more important cause a treatment for COVID-19. A dentist by profession, the man who called himself Jersey Joe during an unsucessful U.S. Senate bid more than a decade ago, has been firing off regular press statements praising the drug, hydroxychloroquine, or HCQ, as a treatment for the virus. The drug is not unknown. It is used to treat lupis, rheumatoid arthritis and malaria. In my bone of bones, I think this works, Pennacchio said this morning.

New Jersey should release elderly and pregnant prisoners amid coronavirus crisis, ACLU says

NJ Transit adds buses to alleviate crowding, encourage social distancing

State Board of Education allows students with disabilities to get services online

State financial aid deadline for New Jersey college students extended to June 1

A HARIRI SITUATION Rudy Giuliani wants FDA to fast-track a stem cell therapy for Covid-19; critics see political meddling, by STATs Adan Feuerstein: In recent days, Giuliani has used his Twitter account and podcast to tout the stem cell treatment being developed by a New Jersey biotech company, Celularity, despite scant evidence to date that its therapy will benefit Covid-19 patients. The company is currently seeking permission to start a clinical trial for the treatment. Giuliani, for his part, has been critical of the FDA, accusing it of standing in the way of important treatments. The general reputation of the FDA and I dont mean to be critical at a time like this but it is very slow, Giuliani said in an interview on his podcast with Bob Hariri, Celularitys founder and CEO Experts fear his argument could resonate with Trump, who has not only made Giuliani a close confidant but has long expressed impatience with the FDAs drug approval process. Giuliani could not be reached for comment.

You may remember Dr. Hariri, a Christie donor and former Celgene executive, from this.

PERIOD. LATE START Murphy hits back at Trump claim New Jersey was very late in coronavirus response, by POLITICOs Sam Sutton: New Jersey Gov. Phil Murphy pushed back Wednesday on President Donald Trumps assertion that the state got off to a very late start on coronavirus containment and mitigation, arguing that the Garden State was one of the first to begin preparing for the possibility of a coronavirus outbreak in January. I don't think that theres any state in America that was on this earlier than we were, Murphy said at his coronavirus press briefing, adding that Washington state where the first domestic case of coronavirus was discovered in January also responded rapidly. The facts dont support that. Period, full stop. At Tuesdays White House coronavirus briefing, Trump said that while he believes Murphy and New York Gov. Andrew Cuomo responded effectively to the public health crisis, they got off to a very late start" on containment.

Booker: Heres where all the stimulus checks will be going in New Jersey

Cerra to head N.J. League Of Municipalities

Dononhue: Bloomberg self-financing in recent presidential campaign makes past NJ mega-spenders look like skinflints

IM CONFIDENT HELL SURVIVE THE VIRUS, BUT CAN HE SURVIVE NOT GOING TO THE TURTLE BACK ZOO? Essex County Executive Joe DiVincenzo is latest N.J. official to test positive for coronavirus, by NJ Advance Medias Anthony G. Attrino: Essex County Executive Joseph N. DiVincenzo Jr., who has been self-quarantined for more than a week, has tested positive for the coronavirus, he announced Wednesday. I decided to get tested after experiencing a fever for several days and have been self-quarantined since March 21, DiVincenzo, 67 said in a Facebook post. DiVincenzo said his symptoms have been mild and that he feels OK.

SHOT Coronavirus in Lakewood: the pandemic has 'changed the way we live and celebrate', by The Asbury Park Press Gustavo Martnez Contreras: After seeing and hearing all the negativity targeting Lakewood in this novel coronavirus pandemic, a Howell man decided to take a drive and see for himself. The video travelogue that 28-year-old Boruch Perlowitz created reveals a township that is ostensibly on lock down, its residents sheltering in place and steering clear of favorite places, sometimes denied by chained and locked doors. As Perlowitz depicts it, usually bustling Lakewood is as sleepy as any other town in New Jersey. I said, let me find out the truth for my neighbors and friends, said Perlowitz. I wanted to do complete honest reporting. If places were open, I would say that places are open. Perlowitz's video aims to counter a narrative in social media that paints Lakewood as a lawless place where residents openly defy Gov. Phil Murphy's executive order shuttering businesses, barring large gatherings and requiring social distancing. Perlowitz said that narrative has engendered enmity toward the town's largely Orthodox Jewish community.

CHASER 10 charged at Lakewood engagement party in violation of coronavirus lockdown, cops say

Heres why large gatherings keep happening in Lakewood, as the coronavirus rages in N.J.

From News 12 anchor Kurt Sieglin on his Lakewood school bus tweets, which I included in Playbook earlier this week: In vetting a story, I screwed up yesterday. There were many reasons the tweets went out, but the responsibility is ultimately with me. Its my account. I have a brand to protect. I regret it. Im sorry for any pain or distrust the tweets created for residents who saw it. Much morehere

R.I.P. Five residents dead at New Milford nursing home, 16 test positive for coronavirus, by The Records Lindy Washburn: A nursing home in New Milford where at least five residents have died of complications of coronavirus is Bergen Countys first major outbreak at a long-term care facility. The disease already has nearly filled area hospitals. Sixteen residents and six staff members at Care One New Milford, known as Woodcrest, have tested positive for coronavirus and others are being tested, the company said late Tuesday night. Additional deaths at the facility also are being investigated to see if the residents had coronavirus.

Prosecutor shoots down idea of signs to label homes of quarantined"

A New York radio reporter, a party on LBI, and now 2 dead from coronavirus

Teaneck officials see signs of progress on COVID-19 because of lockdown

[Red Bank] official recovered from coronavirus. Now, he hopes to donate his plasma to critically ill patients

Red Bank councilman secures pandemic relief donations from more than 100 elected officials

Why the Hoboken mayor is asking residents to hold off food shopping for a couple days

Ex-Jersey City official who pleaded guilty to accepting $300 bribe loses pension appeal

100% THAT DISH Lizzo sends food to N.J. hospital, says were praying for you everyday, by NJ Advance Medias Bobby Olivier: After a hefty food donation from a pop superstar, Community Medical Center is hopefully feeling 'Good As Hell.' Lizzo, the breakout 'Truth Hurts' singer, sent food to the Toms River hospital Monday to thank the medical staff for their hard work battling the coronavirus outbreak. Hello Toms River! Lizzo said in a video posted by RWJBarnabas Monday. Thank you for working so hard for us. I wanted to show a token of my appreciation and just drop off some food, I hope you enjoy the meals.

R.I.P. Fountains of Waynes Adam Schlesinger Dead at 52 From Coronavirus, by Rolling Stone's Jon Blistein: "Adam Schlesinger, co-founder of the New Jersey power-pop group Fountains of Wayne and Emmy- and Grammy-winning songwriter for film, television, and theater, died Wednesday from complications related to COVID-19. He was 52."

R.I.P. N.J. ER doctor who twice survived cancer dies a week after developing coronavirus symptoms

Losing your job overnight: How NJ's LGBTQ community is affected by the coronavirus

Manahan: Coronavirus update: Wake up, N.J.! Florida is trying to kill us (and pin the blame on us)

Continue reading here:
North Jersey hitting the surge - Politico

A word for those risking their lives amid the coronavirus crisis: Thanks – TwinCities.com-Pioneer Press

`It wasnt long after the events of Sept. 11, 2001, that cops, firefighters, first responders and volunteers from across the country and the world were lauded as heroes and temporarily replaced celebrities as the guest stars on talk shows.

The acknowledgment lasted for a while before actors hawking movies and pundits plugging books became the norm again.

As for the most affected first responders those who risked their health and spent weeks sifting through the rubble of the World Trade Center for remains and evidence too many succumbed to cancer and respiratory illnesses that took their lives or permanently scarred them physically and emotionally.

Hopefully, the workers now on the front line of the coronavirus crisis will receive a far more enduring tribute and recognition. Quite a number of them have been infected and some have died while trying to treat patients in their care. They range from the Chinese physician who sounded the first warning of this novel virus to doctors and nurses and others here who have come down with the deadly infection. Add the Italian pastor who died after willingly giving up his ventilator for a younger COVID-19 patient.

I know of this front-line work first hand.

Nine years ago this week on April Fools Day I got the news that I had multiple myeloma, a cancer of the plasma cells. More than 32,000 American adults are diagnosed annually with the incurable disease; more than 12,000 die of complications from it. I was informed I had the worst stage of it. Close to 80 percent of my plasma cells were cancerous. Tests also discovered fractured vertebrae and weakened bones byproducts of the cancer. The average survival rate for Stage III folks like me is 29 months, though treatment protocols have improved over the years.

I went through a year of chemo and a ruptured appendix during aggressive treatment that left me with an ugly but necessary vertical scar that wiped out my belly button. Throw in two autologous stem cell transplants as well as several bouts of pneumonia and other weird respiratory emergencies throughout the years.

Nine years later Im still above ground. I can still work, hoop and salsa, and I checked off some wishes Iike swimming with dolphins and experiencing the worlds second longest zipline. My only treatment since late 2012 is ingesting a daily Revlimid pill that doctors believe is keeping my cancer at below microscopic levels. My gut tells me it might also be the occasional Reeses Pieces, though I place my trust in the medical and scientific communitys assessment.

But Im blessed, thanks to my caretaker wife, the support from my family and friends, and the incredible knowledge and care I was given by those front-line health care workers who were with me step by step. Many are now dealing with the COVID-19 outbreak as well as the normal workload.

They include Dr. Mark Wilkowske, chief of oncology at the Frauenshuh Cancer Center in St. Louis Park, and Drs. Daniel Weisdorf, Philip McGlave and the team at the University of Minnesota Bone Marrow Transplant Program.

But I also am in debt to the long line of physicians, nurses and support staff who have helped me and many others recover from serious illnesses and other medical challenges throughout the years. We now see them profiled on TV sacrificing their own health, rightly pointing out the lack of official preparedness, and working double shifts while juggling family and emotional needs.

I have nothing against well-deserving celebrities. Whether they are musicians, actors or athletes, many have also stepped to the plate to entertain from home, donate to relief efforts or share words of support and solace through social media and other venues. But so have ordinary folks from all corners of the nation.

Maybe, when we do get back to normal, if we ever do, lets not forget what these health care folks and support staff are doing now, day in and day out. I know I wont.

Lets make that gratitude and star treatment last longer than it did 19 years ago.

Read the rest here:
A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press

AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant – SurvivorNet

When we have a patient whose AML has come back, the goal is to get them into a remission so we can take them to a stem cell transplant., saysDr. Tara Lin, director, Acute Leukemia Program, University of Kansas Medical Center. This starts with Drugs such asIvosidenib orEnasidenib, which are important because they can help us get patients into remission and then bridge to transplant.

Early trials and published trials of these drugs show that about 30% of these patients will go into remission. Among them, a smaller proportion of patients will go on to have a stem-cell transplant.That smaller proportion reflects that some patients, often older ones, who may choose not to go on to a stem cell transplant for reasons not fully disclosed.

But that would be the be long-term goal certainly for a younger fit patient with an IDH-1 or IDH-2 mutation whose going to receive these drugs as therapy in relapse, says Dr. Lin. The goal would be to put them back into a remission not with the expectation that these oral drugs will keep them in remission forever but that we can put them into a deep enough remission so that we can take them on to transplant which, at least, has a potentially curative option.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Tara Lin is an Associate Professor of Medicine at The University of Kansas Medical Center. She specializes in acute leukemia and cancer stem cell targeted therapies. Read More

When we have a patient whose AML has come back, the goal is to get them into a remission so we can take them to a stem cell transplant., saysDr. Tara Lin, director, Acute Leukemia Program, University of Kansas Medical Center. This starts with Drugs such asIvosidenib orEnasidenib, which are important because they can help us get patients into remission and then bridge to transplant.

Early trials and published trials of these drugs show that about 30% of these patients will go into remission. Among them, a smaller proportion of patients will go on to have a stem-cell transplant.That smaller proportion reflects that some patients, often older ones, who may choose not to go on to a stem cell transplant for reasons not fully disclosed.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Tara Lin is an Associate Professor of Medicine at The University of Kansas Medical Center. She specializes in acute leukemia and cancer stem cell targeted therapies. Read More

See more here:
AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant - SurvivorNet